virologic

Broadly, two studies submitted to the FDA in support of boceprevir showed more patients responded to treatment by achieving a so-called sustained virologic response.

Hepatitis C Drugs Await FDA Approval Jennifer Corbett Dooren 2011

The addition of boceprevir to peginterferon-ribavirin resulted in significantly higher rates of sustained virologic response in previously treated patients with chronic HCV hepatitis C genotype 1 infection, as compared with peginterferon-ribavirin alone, the authors concluded.

New drug may boost hepatitis C treatment 2011

Vertex submitted two main studies to the FDA in support of Incivek, showing that more patients responded to treatment by achieving a so-called sustained virologic response—essentially a cure—and in a shorter period of time than current hepatitis C therapy.

Hepatitis C Drug Approved Thomas Gryta 2011

One study involving boceprevir found that 66% of patients receiving that drug, together with pegylated interferon and ribavirin, had a sustained virologic response, compared with 38% who received the current, standard therapy of just pegylated interferon and ribavirin.

FDA Panel Backs Merck Hepatitis C Drug Jennifer Corbett Dooren 2011

The addition of boceprevir to peginterferon-ribavirin resulted in significantly higher rates of sustained virologic response in previously treated patients with chronic HCV hepatitis C genotype 1 infection, as compared with peginterferon-ribavirin alone, the authors concluded.

New drug may boost hepatitis C treatment 2011

Debra Birkrant , the director of FDA's antiviral-drugs division, said the products appear to increase sustained virologic response rates, essentially the cure rate, "to more than 30% above what we have today."

FDA Panel Backs Merck Hepatitis C Drug Jennifer Corbett Dooren 2011

The primary goal was to measure "sustained virologic response," or SVR, which means undetectable virus levels 24 weeks after the end of treatment.

Merck Reports Encouraging Results for Hepatitis C Treatment 2010

The primary goal was to measure "sustained virologic response," or SVR, which means undetectable virus levels 24 weeks after the end of treatment.

Corporate Watch 2010

The board stopped the high viral-load Epzicom arm and in a press release said it was due to high virologic failure.

Patient Investor: Interview With Tony Yao Leslie P. Norton 2008

"Only 38% of patients in the viramidine treatment arm achieved sustained virologic response, compared to 52% patients in the ribavirin treatment control arm," wrote analyst Andrew McDonald.

Valeant Plunges On Disappointing Trial Data 2006